Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06712797 · ClinicalTrials.gov registry record · NA

Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center

A NA study of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Active
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06712797 is a NA study of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 24 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06712797, a NA study of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this Study is to assist in implementing a practical, easy-to-adopt lifestyle intervention that optimizes patient outcomes and minimizes pancreatic ductal adenocarcinoma (PDAC) risk.

Interventions

  • BEHAVIORAL Physical Activity (PA)
  • BEHAVIORAL Nutrition (N)

Study Locations (1)

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-02-19
Est. Completion 2027-11
Phase NA

What the Registry Record Tells You About NCT06712797

The ClinicalTrials.gov registry entry for NCT06712797 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (96% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Physical Activity (PA) is the first listed.

NCT06712797 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06712797 about?

NCT06712797 is a clinical study titled "Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center". The purpose of this Study is to assist in implementing a practical, easy-to-adopt lifestyle intervention that optimizes patient outcomes and minimizes pancreatic ductal adenocarcinoma (PDAC) risk.

What is the current status of trial NCT06712797?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-02-19. Estimated completion is 2027-11.

What conditions does trial NCT06712797 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Intraductal Papillary Mucinous Neoplasm.

What interventions are being tested in trial NCT06712797?

The interventions under investigation include: Physical Activity (PA) (BEHAVIORAL), Nutrition (N) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06712797?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06712797 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.